Trial · NCT02055482
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in local laboratory hemoglobin level from baseline | Baseline up to 36 months | |
| Primary | Number of participants with serious adverse events (SAEs) and adjucated adverse events as a measure of safety and tolerability | Up to 36 months | |
| Primary | Number of participants with liver function-related AEs including abnormal liver function tests and any hospitalization | Up to 36 months | |
| Secondary | Time within hemoglobin target range (10.0 to 12.0 g/dL) | Up to 36 months | |
| Secondary | Duration of treatment exposure | Up to 36 months | |
| Secondary | Number of subjects requiring titration of dose | Up to 36 months | |
| Secondary | Change of reticulocyte count from baseline of this study | Baseline up to 36 months | |
| Secondary | Change of red blood cell count from baseline of this study | Baseline up to 36 months | |
| Secondary | Change of hematocrit from baseline of this study | Baseline up to 36 months | |
| Secondary | Change of central laboratory hemoglobin level from baseline of this study | Baseline up to 36 months | |
| Secondary | Responders in Hb levels | Up to 36 months | |
| Secondary | Number of subjects meeting specific Hb criteria | Baseline up to 36 months | |
| Secondary | Number of subjects with Hb values >13 g/dL or having excessive Hb increase | Baseline up to 36 months | |
| Secondary | Number of participants with non-serious adverse events | Up to 36 months | |
| Secondary | Change in heart rate (HR) | Up to 36 months | |
| Secondary | Change in blood pressure (BP) | Up to 36 months | |
| Secondary | Laboratory abnormalities | Up to 36 months | |
| Other | Change of reticulocyte count from baseline of study 15141 or 15261 | Baseline up to 36 months | |
| Other | Change of red blood cell count from baseline of study 15141 or 15261 | Baseline up to 36 months | |
| Other | Change of hematocrit from baseline of study 15141 or 15261 | Baseline up to 36 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02055482/registered